Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial und TRANSCEND - Telmisartan randomized assessment study in ACE-I intolerant subjects with cardiovascular disease (30 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 23: TRANSCEND - Telmisartan Randomized AssessmeNt Study in ACE-I INtolerant Subjects with Cardiovascular Disease Abb. 24: TRANSCEND - background Abb. 25: TRANSCEND - objectives Abb. 26: TRANSCEND - patient profile Abb. 27: TRANSCEND - study design Aktuelles Bild - Abb. 28: TRANSCEND - study design Abb. 29: TRANSCEND - primary end point Abb. 30: TRANSCEND - secondary end points
Abbildung 28: TRANSCEND - study design
Patients will be randomized to: + telmisartan 80 mg once daily + placebo. It is intended to enrol 2500 patients in each treatment arm. Patient recruitment into TRANSCEND will begin in 2001. The study is expected to complete within 5.5 years.
 
TRANSCEND - study design
Vorheriges Bild Nächstes Bild   


Abbildung 28: TRANSCEND - study design
Patients will be randomized to: + telmisartan 80 mg once daily + placebo. It is intended to enrol 2500 patients in each treatment arm. Patient recruitment into TRANSCEND will begin in 2001. The study is expected to complete within 5.5 years.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung